Experts

Timothy Snail

Vice President

Timothy Snail - Engagements

Pharmaceuticals
Antitrust & Competition
CRA assisted counsel to Teva, a major pharmaceutical manufacturer, in responding to a preliminary injunction sought by a competitor. The team was led by Tim Snail and included Duke Shao and others. Read more
Health Care, Life Sciences
Antitrust & Competition
A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent... Read more
Antitrust & Competition
CRA assisted counsel to Valmet Inc., a global developer and supplier of technologies, automation, and services for the pulp, paper, and energy industries, in a contract dispute wherein it won dismissal on liability grounds. Read more
Class Certification
CRA advised counsel to Visionworks, a national prescription eyeglasses retailer, in its successful defeat of class certification in a matter alleging false advertising. Read more
Health Care, Life Sciences
Antitrust & Competition, Damages & Valuation
In a matter involving an antitrust counterclaim, a generic pharmaceutical manufacturer alleged that a blockbuster brand manufacturer attempted to monopolize the market and delay entry of the generic product. Read more
Health Care, Life Sciences
Antitrust & Competition
A CRA expert was retained to analyze class certification issues relating to allegations that a pharmaceutical product was marketed for off-label uses and caused direct and indirect purchasers to pay for billions of dollars unnecessarily. Read more
Health Care, Life Sciences
Antitrust & Competition
A CRA expert was retained in an antitrust matter involving patent settlement agreements between branded and generic pharmaceutical manufacturers that involved so-called ‘reverse payments’. Read more
Antitrust & Competition
CRA provided testimony in support of Masimo in its successful effort to refute monopolization, tying, and other antitrust counterclaims following a competitor’s infringement of its medical device patents. Read more